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OBJECTIVES We sought to determine whether the association of higher C-reactive protein levels (CRP)
and more extensive coronary artery disease (CAD) explains the high cardiovascular risk of
renal insufficiency (RI).
BACKGROUND Renal insufficiency and renal failure (RF) have been associated with increased cardiovascular
risk in several studies, and it has been suggested that this association may be due to higher
CRP levels and greater extent of CAD. To what extent CRP or severity of CAD explains this
risk is uncertain.
METHODS A total of 1,484 patients without myocardial infarction (MI) undergoing angiography were
entered and followed for 3.0  1.6 years; RI and RF were defined as estimated glomerular
filtration rates (GFR) of 30 to 60 and 30 ml/min; CRP was measured by immunoassay and
 1.0 mg/dl defined as elevated. A CAD score was determined by extent and severity of
angiographic disease. Multivariate Cox regressions were performed using seven standard risk
factors, homocysteine, GFR, CRP, and CAD score.
RESULTS Mean age was 64 years, and 67% were men; CAD was absent in 24%, mild in 11%, and severe
(70% stenosis) in 60%; CRP and CAD scores increased with declining renal function
(median CRP: 1.2, 1.4, 2.2 mg/dl, p  0.001 and CAD score: 8.1, 8.7, 9.3, p  0.008 for
no-RI, RI, and RF). During follow-up, 208 patients (15%) died or had nonfatal MI.
Unadjusted hazard ratio (HR) for death/MI was 2.3 for RI and 5.1 for RF (p  0.0001).
Adjustment for CRP (HR, 2.2, 4.5), CAD score (HR, 2.1, 5.1), and all other risk factors
(HR, 1.7, 4.5) had minimal or modest impact on RI and RF risk; HR increased to 5.4 (p 
0.001) for presence of both elevated CRP and RI/RF.
CONCLUSIONS Renal insufficiency, CRP, and angiographic CAD, although correlated, are largely indepen-
dent predictors of cardiovascular risk, suggesting the importance of both inflammation and as
yet undefined RI-related risk factors. (J Am Coll Cardiol 2003;42:57–63) © 2003 by the
American College of Cardiology Foundation
Renal insufficiency (RI) and renal failure (RF) have been
associated with increased cardiovascular (CV) risk in several
studies (1,2), whereas, in other studies (3,4), baseline
creatinine was not predictive, possibly due to a low preva-
lence of coronary artery disease (CAD) at baseline. It has
been suggested that RI may predict CV events due to an
association with more severe CAD (5). It has also been
hypothesized that RI is predictive of CV events due to the
presence of an inflammatory state associated with chronic
elevations of C-reactive protein (CRP) (6). Indeed, several
studies have shown CRP levels to be elevated in RF, and
high CRP levels in dialysis patients are predictive of future
CV events (7–11). To what extent higher CRP levels and
more extensive CAD in RI patients are responsible for the
associated increases in CV risk has not been clearly defined.
METHODS
Study objectives. Our principal study objectives were to
determine: 1) whether RI was predictive of death or
myocardial infarction (MI); 2) whether RI was associated
with atherosclerotic burden and CRP, and, if so, whether
the predictive value of RI would remain after multivariate
adjustment; 3) whether RI is predictive of death or MI in
patients without angiographic CAD; 4) whether the pre-
dictive value of CRP differs among subjects with normal
renal function, RI, or RF; and 5) the magnitude of the
relative risk of these factors.
Patients and follow-up. The study sample included con-
secutive consenting patients at a single hospital (LDS
Hospital, Salt Lake City, Utah) undergoing coronary an-
giography between 1994 and 2000 for evaluation of symp-
toms suggestive of stable or unstable angina, and who had
complete data recorded. Patients with acute MI (whose
CRP levels are affected by an acute phase reaction) were
excluded. Creatine kinase-MB, if drawn before angiogra-
phy, was uniformly normal (this series was enrolled before
From the *Cardiovascular Department, LDS Hospital, and †Divisions of Cardi-
ology and Nephrology, University of Utah School of Medicine, Salt Lake City, Utah.
Supported, in part, by grants from the Deseret Foundation and the National Institutes
of Health (NIH, 5 T32 HL-7576).
Manuscript received November 22, 2002; revised manuscript received March 12,
2003, accepted March 27, 2003.
Journal of the American College of Cardiology Vol. 42, No. 1, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)00564-3
widespread testing with troponin assays). Most subjects
were residents of Utah, southwestern Idaho, or southeastern
Wyoming, a population genetically representative of U.S.
Caucasians. The study met approval by the hospital’s
institutional review board.
The risk factors used in multivariable analyses included
age, sex, diabetes, smoking history (current or 10 pack
years), family history of CAD, diagnosis of hypertension,
diagnosis of hyperlipidemia, homocysteine (n  1,128),
glomerular filtration rate (GFR), CAD score, and CRP.
Clinical events during follow-up were determined
through telephone calls and hospital records, with supple-
mental information from the Utah and national Social
Security death registry enabling 100% probabilistic deter-
mination of vital status.
Determination of CAD severity. All angiograms were
reviewed by an attending cardiologist blinded to CRP level
and future outcomes, and each lesion was visually estimated
for percent diameter stenosis rounded to the nearest 10%.
The presence of a mild/moderate (10% to 60%) or a severe
lesion (70% to 100%) in the left anterior descending, the
circumflex, or the right coronary artery defined the vessel as
a mild/moderately or severely affected vessel (or both).
The extent of CAD was quantified by a CAD score,
which has previously been determined to be the strongest
angiographic predictor of future death/MI in our database
(12). The score was obtained by adding the number of
distinct lesions with 10% to 60% stenosis (range, 0 to 18),
the number of distinct lesions with 70% stenosis (range, 0
to 14), the number of major vessels with at least one
moderate stenosis (range, 0 to 3), and the number of vessels
with at least one severe stenosis (range, 0 to 3). The CAD
score ranged from 0 to 28.
Determination of CRP. C-reactive protein was quantified
by an intermediate sensitivity fluorescence polarization im-
munoassay (Abbott Diagnostics, Chicago, Illinois). The test
is standardized to the International Federation of Clinical
Chemistry International Reference Preparation for Plasma
Proteins. The within-run coefficient of variation for a
1.78-mg/dl standard is 3.7%. Between-run coefficients of
variation are 3.9% for a 0.74-mg/dl standard and 3.0% for a
9.08-mg/dl standard.
We chose a priori to define an elevated CRP as 1.0
mg/dl, a commonly used cut-point to define high-risk in the
literature and our previous studies in CAD populations; this
level exceeds the 98th percentile for clinically normal indi-
viduals (Abbott Laboratories).
Determination of RI and RF. We calculated a GFR on all
subjects using a simplified formula (13) from the Modifi-
cation of Diet in Renal Disease study (MDRD). The
MDRD formula used predictors of GFR (age, gender,
ethnicity, serum urea nitrogen, and albumin) and demon-
strated better estimation of GFR than the Cockcroft-Gault
formula or 24-h creatinine clearance. Renal insufficiency
was defined a priori as a GFR 60 ml/min (which approx-
imated the lower quartile) and renal failure as GFR  30
ml/min.
Statistical considerations. Baseline demographic and lab-
oratory information is presented as mean (SD) for contin-
uous variables and frequencies for discrete variables. Com-
parisons among groups used analysis of variance for
continuous variables and chi-square testing for discrete
variables. Survival statistics were used for risk determina-
tions. The primary outcome variable was the combination of
death (all-cause) or MI. Only the first event was counted as
an end point. Secondary outcome variables were death and
MI alone. Cox regression analysis was used for assessment
of the relative hazard of these events over time. Both
univariate and multivariate analyses were performed using
SPSS for Windows, version 10.0 (Chicago, Ilinois). Cox
multivariate adjustments of hazard ratios used forced entry
and backward conditional stepwise approaches to determine
parsimonious, best-fitting models.
RESULTS
Subject population and demographics. A total of 1,484
subjects were enrolled who had angiographic and baseline
demographic information, a baseline high-sensitive CRP
level, and data needed to calculate GFR. Subjects were
followed for up to 6.3 years (mean, 3.0  1.6 years).
Presentation was diagnosed as stable angina for 72% and
unstable angina for 28% of subjects. Mean age was 64 years;
67% were men; 24% had no angiographic CAD, 11% had
mild-moderate CAD, and 60% had severe CAD (70%
stenosis). Baseline demographics are presented in Table 1 by
renal function category. Discharge rates of medications were
43% for angiotensin-converting enzyme (ACE) inhibitors,
12% for beta-blockers, and 17% for statins, and these
frequencies did not differ significantly by groups except for
somewhat greater use of ACE inhibitors in RI/RF patients
(Table 1).
Glomerular filtration rate correlated negatively with age
(0.33, p  0.001), homocysteine (0.18, p  0.001),
CRP (0.16, p  0.001), CAD score (0.08, p  0.003),
diabetes (0.05, p  0.04), and hypertension (0.05, p 
0.05), but the strength of the correlations was poor.
Renal function and CRP. The mean study group GFR
was 73 ml/min, and the median CRP was 1.3 mg/dl; CRP
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CAD  coronary artery disease
CRP  C-reactive protein
CV  cardiovascular
GFR  glomerular filtration rate
HR  hazard ratio
MDRD  Modification of Diet in Renal Disease study
MI  myocardial infarction
RF  renal failure
RI  renal insufficiency
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levels increased with declining renal function: median CRP
was 1.2 mg/dl without RI, 1.4 mg/dl for RI, and 2.2 mg/dl
for RF (p  0.001); CRP correlated negatively with GFR
(Pearson’s correlation coefficient, 0.16, p  0.001). Fac-
tors positively correlated with CRP levels (diabetes, 0.07, p
 0.006; CAD score, 0.08, p 0.003; age, 0.10, p 0.001)
were more prevalent in patients with RI/RF, and factors
negatively correlated with CRP (hyperlipidemia0.09, p
0.001) were less prevalent, partially accounting for associa-
tions of CRP and GFR.
Renal function and CAD score. The presence of angio-
graphic CAD did not differ significantly by renal function
category (Table 1). However, among patients with angio-
graphic CAD, the extent/severity of CAD, as measured by
the CAD score, increased with declining renal function:
from 8.1 without RI, to 8.7 with RI, to 9.3 with RF (p 
0.008). The CAD score negatively correlated with GFR
(0.08, p  0.003) and positively correlated with known
CAD risk factors: age (0.25, p  0.001), hyperlipidemia
(0.25, p  0.001), diabetes (0.15, p  0.001), hypertension
(0.14, p  0.001), and family history (0.06, p  0.01).
Predictive value of renal function for death or MI.
During a mean follow-up of 3.0 1.6 years, there were 235
events of all-cause death or nonfatal MI in 208 patients
(15%). The hazard ratio (HR) for death or MI in univariate
analysis was 2.3 for RI and 5.1 for RF (p 0. 0001); HRs
for RI and RF were greater for death (3.0, 7.6, respectively)
than for MI alone (1.8, 3.0) (Table 2). Although CRP
significantly correlated with GFR, adjustment for CRP only
slightly altered the predictive value for death/MI for RI
(HR, 2.2) and RF (HR, 4.5). Similarly, adjustment for
CAD score had minimal effect on the predictive value of RI
(HR, 2.1) and did not alter the predictive value of RF (HR,
5.1). Homocysteine also correlated with GFR and predicted
death or MI (HR, 1.3 for level 15 mg/dl, p  0.04);
however, adjustment for homocysteine also did not signif-
icantly alter the HR associated with RI and RF (2.1 and
6.2). Finally, after full multivariate adjustment, the HR for
death or MI was only modestly affected for RI (1.7) and RF
(4.5) (Table 3).
Even when the analysis was confined to patients with
creatinine 1.5, a GFR 60 remained an independent
predictor in multivariate analysis with an HR of 1.5 (p 
0.02). In contrast, a creatinine of 1.3 to 1.5 did not define a
high-risk group (HR, 1.1; p  0.73). Using mild renal
Table 2. Univariate and Bivariate (Adjusting for CRP or CAD
Score) Hazard Ratios for Death and/or MI for RI or RF, and
Univariate Risk Among Patients With and Without ACE
inhibitors at Discharge
RI RF
Univariate HR for death 3.0 (2.1–4.2) 7.6 (4.5–12.6)
Univariate HR for MI 1.8 (1.1–3.0) 3.0 (1.1–8.2)
Univariate HR for death/MI 2.3 (1.7–3.1) 5.1 (3.2–8.3)
HR for death/MI adjusted for CRP 2.2 (1.7–3.0) 4.5 (2.8–7.4)
HR for death/MI adjusted for CAD
score
2.1 (1.6–2.8) 5.1 (3.2–8.3)
Univariate HR for death/MI among
patients discharged on ACE
inhibitor
1.9 (1.3–2.9) 4.5 (2.1–9.1)
Univariate HR for death/MI among
patients without ACE inhibitor at
discharge
2.5 (1.7–3.8) 5.6 (2.9–10.9)
Renal failure (RF) was defined as GFR 30 and renal insufficiency (RI) as GFR
30–60 mg/dl.
HR  hazard ratio; RF  renal failure; RI  renal insufficiency. Other
abbreviations as in Table 1.
Table 1. Baseline Demographic Data
GFR >60
(n  1,104)
GFR 30–60
(n  329)
GFR < 30
(n  51)
p Value
(Linearity)
Age, mean 62 70 62  0.001
GFR, mean (ml/min) (range) 83 (60–150) 50 (30–59.9) 17 (3.7–29.9)  0.001
Creatinine, mean (mg/dl) (range) 0.9 (0.5–1.4) 1.4 (0.9–2.3) 4.8 (1.7–14.4)  0.001
CRP, median (mg/dl) 1.2 1.4 2.2  0.001
Angiographic CAD present 75% 80% 76% NS
CAD score (n  1,126 with CAD) 8.1 8.7 9.3 0.008
Hypertension 55% 63% 71% 0.001
Hyperlipidemia 50% 45% 37% 0.02
Diabetes 17% 20% 47%  0.001
Glucose, mean (random, mg/dl) 118 120 147  0.001
Family history of CAD 36% 28% 25% 0.002
Smoker 24% 16% 10%  0.001
Homocysteine (n  1,128, median) 6.7 6.8 9.7  0.001
ACE inhibitor at discharge 41% 50% 49% 0.004
Beta-blocker at discharge 19% 22% 17% NS
Statin at discharge 18% 13% 12%  0.001
Death 7% 19% 37%  0.001
MI 5% 8% 8% 0.03
Death or MI (first event) 10% 23% 37%  0.001
Days to event or end of follow-up 1,105 1,065 707  0.001
Mean values unless noted otherwise in groups of normal renal function (GFR 60 ml/min), renal insufficiency (GFR 30–60 ml/min), and renal failure (GFR 30 ml/min).
Diagnoses of hypertension, hyperlipidemia, family history, and diabetes are those as recorded by primary physician. Smoker represents current tobacco use or history of  10
pack years.
ACE  angiotensin-converting enzyme; CAD  coronary artery disease; CRP  C-reactive protein; GFR  glomerular filtration rate; MI  myocardial infarction.
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insufficiency as previously defined by a creatinine of 1.4 to
2.3 (1), the multivariate adjusted HR for death or MI was
1.6 (p  0.02). Finally, using a creatinine of 2.5 to define
renal failure, compared with a creatinine of 1.3, the
multivariate adjusted HR for death or MI was 5.0 (p 
0.001). These findings suggest similar predictive value of
creatinine and GFR once creatinine is clearly elevated above
normal, whereas GFR is a stronger predictor when creati-
nine levels may represent either normal renal function or
mild-moderate renal insufficiency (i.e., creatinine 0.9 to
1.5). If RF was defined as a GFR 40 ml/min, the HR for
death/MI was modestly lower (unadjusted HR, 4.2 vs. 5.1).
The HR for the RI group with a GFR of 40 to 60 ml/min
was similar (unadjusted HR, 2.1 vs. 2.3).
Patients with RI or RF were more likely to be discharged
on ACE inhibitors, but not beta-blockers or statins (Table
1). In multivariate analysis, the use of ACE inhibitors at
discharge was associated with a reduction in the risk of
death/MI (HR, 0.72, p  0.03), while beta-blockers or
statins were not (Table 3). In univariate analysis, the risk of
death/MI was lower among patients discharged on ACE
inhibitors (HR, 1.9 for RI and 4.5 for RF) compared with
patients not discharged on ACE inhibitors (HR, 2.5 and
5.6, respectively) (Table 2). Similarly, the risk of death/MI
was lower among patients discharged with beta-blockers
(HR, 1.5 for RI, 3.0 for RF) than those without beta-
blockers (HR, 2.3 and 6.9, respectively), and among patients
discharged on statins (HR, 1.6 and 3.8) than those without
statins (HR, 2.4 and 5.2).
Predictive value of renal function in subjects without
CAD. Three hundred fifty-one patients underwent an-
giography for suspected cardiac disease but were found to
have angiographically normal coronary arteries. The risk of
incident death or MI is generally low in such patients, yet
angiographically non-apparent CAD may still be present
and progress or result in plaque rupture. In this group of
subjects, the risk of MI was much higher in the presence of
RI/RF (5.2% vs. 0.7%; multivariate HR 10.2 [1.7 to 62.3],
p  0.01) as was the risk of death (24.7% vs. 3.9%;
multivariate HR 6.5 [3.1 to 13.7], p  0.001).
Predictive value of CRP and renal function together.
Elevation of CRP resulted in an HR of death/MI of 2.6 (1.7
to 3.9, p  0.001). The predictive value of elevated CRP
was modestly increased among patients with RI/RF (HR,
2.9; p  0.004) than among patients without RI (HR, 2.1;
p  0.003). The combined presence of both RI/RF and
elevated CRP, compared with neither, predicted a dramatic
increase in risk of death or MI (HR of 5.4 (3.3 to 8.8, p 
0.001) (Figs. 1 and 2). These findings were not significantly
Table 3. Hazard Ratio of Death or Myocardial Infarction in
Multivariate Analysis
Hazard Ratio 95% CI p Value
Renal failure 4.5 2.7–7.3  0.001
Smoker 1.8 1.3–2.6  0.001
CAD score 1.08 1.05–1.11  0.001
Age (per yr) 1.03 1.02–1.05  0.001
Hyperlipidemia 0.53 0.39–0.73  0.001
Renal insufficiency 1.7 1.2–2.3 0.001
CRP 1.0 mg/dl 1.9 1.2–2.8 0.003
Diabetes 1.5 1.1–2.2 0.014
ACE inhibitor use 0.72 0.54–0.97 0.03
Renal failure was defined as GFR 30 and renal insufficiency as GFR 30–60 mg/dl.
Abbreviations as in Table 1.
Figure 1. Kaplan-Meier event-free (first event of death or myocardial infarction [MI]) survival curves for patients with glomerular filtration rate GFR 60
mg/dl (renal insufficiency [RI], n  77), C-reactive protein (CRP) 1.0 mg/dl (CRP, n  769), both (n  303) or neither (n  335).
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altered if patients with severe RF (i.e., GFR  20) or
advanced age (i.e., age  80) were excluded from analysis.
DISCUSSION
Study summary and perspective. In this large, well-
characterized, prospectively followed cohort of subjects with
suspected CAD undergoing angiography, we have demon-
strated the strong associations of renal insufficiency and
renal failure with incident death or MI; CRP and CAD
score showed modest to moderate inverse associations with
renal function and CAD score, yet adjustment for CRP, for
CAD score, or for all 10 risk factors had minimal or modest
impact on RI/RF risk. Specifically, the risk of RI and RF
were largely independent of CRP elevation, extent of CAD,
homocysteine levels, and traditional risk factors; we were
able to account for only about 25% of the risk of RI/RF due
to associations with confounding factors.
The use of ACE inhibitors at the time of discharge did
modestly lower the associated risk of RI/RF. This is
consistent with previous randomized trials showing a reduc-
tion in CV events with the use of ACE inhibitors in RI.
Statins and beta-blockers did not prove to be independent
predictors of protection from death/MI, possibly due to
small numbers of patients on therapy.
The study does confirm that CRP levels are elevated in
RI/RF, and elevated CRP was a predictor of incident events
among patients with concomitant RI/RF. Importantly, HR
increased impressively (to 5.4) when both elevated CRP and
RI/RF were present; CRP levels may have decreased over
time (due to increased utilization of lipid-lowering therapy
or aspirin) or may have increased (due to the progression of
CAD and CV risk factors). Changes in CRP levels over
time would generally tend to weaken any association of
CRP and death/MI. If the association is weakened, the
associated risk of RI for death/MI due to elevation of CRP
could also be weakened. However, at baseline, the correla-
tion of RI/RF and CRP was modest in comparison with the
association of CRP with future death/MI. Repeat CRP
values over time would have been valuable, but is unlikely to
explain the associated risk of RI. Although the presence of
angiographic CAD was only slightly and nonsignificantly
more frequent among patients with RI, the use of a sensitive
CAD score demonstrated greater severity/extent of CAD in
the setting of RI/RF. Despite this association, the predictive
value of RI/RF was not accounted for by the presence of
more extensive CAD. Importantly, RI/RF appear to retain
independent predictive value for death or MI in both the
presence and absence of angiographic CAD.
Among patients with angina who have a “normal” angio-
gram, the presence of RI/RF remains associated with a high
risk for future MI or death. Thus, aggressive risk factor
modification may be helpful in such patients.
Taken together, these study findings suggest that RI/RF,
CRP, and angiographic CAD, although weakly correlated,
are largely independent predictors of cardiovascular risk.
Thus, in addition to inflammation and atherosclerosis, other
unmeasured RI-related factors are operative in determining
the excess cardiovascular risk associated with RI/RF.
Historical perspective. Prior studies have reached different
conclusions on the independent predictive value of RI for
cardiovascular events. In the MRFIT and TOMHS studies
(4), the change in creatinine over time was predictive of
future events although the baseline creatinine was not. In
the Framingham Heart study (3), mild RI (creatinine 1.4 to
3.0) was not associated with cardiovascular events at 15
years of follow-up, but it was modestly associated (HR 
1.3) with all-cause mortality in men. It was concluded that
RI predicted future events due to a strong association with
CAD and CAD risk factors. In contrast, recent data from
the Heart Outcomes and Prevention Evaluation trial
showed a significant independent risk for cardiovascular
events with mild RI (1), with an adjusted HR of 1.4 for
cardiovascular death, MI or stroke. The Bypass Angioplasty
Revascularization Investigation (BARI) trial also demon-
strated an association with renal insufficiency and the risk of
recurrent hospitalization, bypass surgery, and death (14).
Other recent trials have also demonstrated independent
predictive values of RI for mortality. Best et al. (15)
evaluated over 5,000 patients undergoing percutaneous cor-
onary intervention and found one-year mortality to be 1.5%
for GFR 70 ml/min, 3.6% for GFR 50 to 69 ml/min,
7.8% for GFR 30 to 49 ml/min, 18.3% for GFR  30
ml/min, and 19.9% for patients on dialysis. The risk of
future MI was also strongly correlated to renal function.
Walsh et al. (16) demonstrated an adjusted HR of 2.4 for
mortality among patients with elevated creatinine after MI.
Wright et al. (17) demonstrated a graded risk for in-hospital
mortality by renal function. The adjusted HR for death after
discharge was 2.4 for mild RI, 2.2 for moderate RI, 1.9 for
RF, and 5.4 for end-stage renal disease. Patients with worse
Figure 2. Absolute percentage of death or myocardial infarction (MI)
among patients with glomerular filtration rate 60 mg/dl ( renal
insufficiency [RI]), C-reactive protein (CRP) 1.0 mg/dl (CRP), both
or neither, during mean follow-up of three years. Solid bars  MI; open
bars  death.
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renal function were less likely to receive adjunctive and
reperfusion therapy, and failure to receive these treatments
was associated with an increased risk of death during
follow-up. Shlipak et al. (18) analyzed over 130,000 patients
with MI and demonstrated an adjusted HR for one-month
mortality of 1.7 for mild RI (creatinine 1.5 to 2.4) and 2.4
for moderate RI (creatinine 2.5 to 3.9). Again, patients with
RI were less likely to receive appropriate adjunctive and
reperfusion therapy, which also was associated with worse
outcomes.
These studies now demonstrate a consistent increase in
the risk of mortality and CV complications with renal
insufficiency. Some of the differences of associated risk
between studies may relate, in part, to the lower sensitivity
of creatinine than GFR for assessing mild renal dysfunction,
definition of renal insufficiency, and differences in the
studied population. Our study is consistent with these prior
studies and demonstrates an increased risk of mortality and
nonfatal MI with RI and RF. In addition, we have dem-
onstrated this risk is not accounted for by the presence of
more severe CAD or higher CRP levels. In contrast to prior
studies, our patients had similar rates of medical therapy
(ACE inhibitors, statins, and beta-blockers) among renal
function groups. This may be due, in part, to a more
homogenous group of selected patients, as all our patients
likely had a reasonable life expectancy as indicated by the
willingness to undergo cardiac catheterization. However, as
with other studies, we also noted an increased HR among
patients not given these medical therapies.
Potential mechanisms of RI-associated risk. A number
of pathogenic mechanisms might account for the elevated
cardiovascular risk associated with RI/RF, but these remain
to be more clearly evaluated. These include elevated serum
calcium X phosphate product (19), hyperparathyroidism
(20), anemia (2), hypoalbuminemia, hyperhomocysteinemia
(21,22), chronic inflammation, and uremic toxins. Asym-
metric dimethylarginine, an innate inhibitor of nitric oxide
synthase, is one molecule that accumulates in renal failure,
possesses all the characteristics of a uremic toxin candidate,
and was associated with independent risk of mortality in a
recent report (23). Other uremia-related toxins likely also
contribute. Consistent with these observations, our study
indicates that substantial risk remains after accounting for
CRP (a marker of inflammation), and homocysteine (an
endothelial toxin in high doses).
Study limitations. The limitations of this study are those
inherent to all prospective but non-randomized registries,
including the influence on results of referral and selection
bias that may be incompletely corrected despite adjustment
for recognized risk factors. Our center has a low proportion
of ethnic minorities, and results in these subgroups may be
different. Data on long-term medication adherence and
changes are not available. However, the study was large, the
results robust and consistent, and adjustment for 10 covari-
ates showed little evidence for affecting the risk of RI/RF.
Also, we have only a single measurement of creatinine,
which may have changed over time, especially in relation to
the dye load of angiography, placing patients with RI at
higher risk. The RF group as defined is a small group. Many
of these patients had end-stage renal disease treated with
dialysis, yet these specifics were not available. The HR of
death or MI is altered somewhat with differing definitions
of RF; however, our results are consistent with prior reports.
Additional risk factors that may associate with RI and poor
outcome (anemia, persistently elevated blood pressure, lipid
levels, proteinuria) were not available for entry into multi-
variate analysis. Quantification of coronary angiographic
findings was limited to the visual interpretation of the
attending cardiologist, which is representative of “real
world” practice. The cause of death was available in less than
half of cases, so that our analyses relied on total rather than
cause-specific (cardiovascular) death. However, among pa-
tients in whom cause of death could be determined, 75%
were cardiovascular.
Conclusions. Renal insufficiency, RF, CRP, and angio-
graphic CAD are each strong and independent predictors of
future death or MI. Although RI is associated with higher
CRP and more extensive CAD, these factors account for
only approximately 10% of the associated risk of RI. Renal
insufficiency and RF remain powerful predictors despite full
adjustment for these and all standard risk factors. Jointly,
high CRP and RI/RF predict a dramatic increase in
death/MI risk, suggesting the importance of both inflam-
mation and as yet undefined RI-related risk factors. These
unrecognized factors provide a challenge for future research
discovery efforts.
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